News & Events:BWXT

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

  BWX Technologies reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. BWX Technologies beat estimated earnings by 9.33%, reporting an EPS of $0.82 versus an estimate of $0.75. Revenue was up $48.90 million from the same period last year.

LYNCHBURG, Va.---- BWX Technologies, Inc. (BWXT) reported second quarter 2022 revenue of $554 million, a 10% increase compared with $505 million in the second quarter 2021. “BWXT delivered a strong second quarter despite a few operational challenges," said Rex D. Geveden, president and chief executive officer.

  ** Pyxis Tankers is likely to report earnings for its second quarter. ** Kandi Technologies Gr is projected to report earnings for its second quarter. ** Tredegar is estimated to report earnings for its second quarter. ** PowerFleet is likely to report quarterly loss at $0.12 per share on revenue of $34.36 million. ** PDS Biotechnology is projected to report earnings for its second quarter.

BWX Technologies Inc (BWXT): * BWXT NAMES SHARON H. SMOOT AS PRESIDENT OF NUCLEAR OPERATIONS GROUP Source text for Eikon: Further company coverage:

BWX Technologies, Inc. (BWXT) has appointed Sharon H. Smoot as president of BWXT’s Nuclear Operations Group, Inc.. In this role, she will have full responsibility for NOG’s mission to provide a complete range of nuclear components and services, including the manufacture of nuclear reactor components for U.S. Navy submarines and aircraft carriers and other nuclear and non-nuclear R&D and component prod...

BWX Technologies, Inc. (BWXT) will issue a press release detailing second quarter 2022 results on Monday, August 8, 2022, after market close and will host a conference call at 5:00 p.m. EDT. Listen-only participants are encouraged to participate and view the supporting presentation via the Internet at www.bwxt.com/investors.

BWXT Canada Secures C$130M Component Manufacturing Contract

BWX Technologies Inc (BWXT): * BWX TECHNOLOGIES CANADA AWARDED C$130 MILLION COMPONENT MANUFACTURING CONTRACT FROM BRUCE POWER. * BWX Technologies Inc (BWXT) - FEEDERS WILL BE MANUFACTURED BY MEMBERS OF UNITED STEELWORKERS LOCAL 2859 AT BWXT CANADA'S CAMBRIDGE, ONTARIO FACILITY. * BWX Technologies Inc (BWXT) - CONTRACT WAS BOOKED IN Q1 OF 2022, AND PRE-PRODUCTION QUALIFICATION WORK FOR PROJECT IS CURRENTLY UNDERWAY.

BWX Technologies, Inc. (BWXT) today announced a contract awarded by Bruce Power valued at approximately CA$130 million in support of Bruce Power’s Major Component Replacement Project. The contract is for the fabrication and supply of replacement feeders for Bruce Power’s reactor units 3, 4, 5, 7 and 8 and represents an integral part of Bruce Power’s MCR Project.

BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products

BWX Technologies Inc (BWXT): * BWXT MEDICAL EXECUTES COMMERCIAL AGREEMENT WITH BAYER FOR SUPPLY OF ACTINIUM-225 BASED PRODUCTS. * BWX Technologies Inc (BWXT) - PARTIES EXPECT SUPPLY TO COMMENCE LATER THIS YEAR. * BWX Technologies Inc (BWXT) - UNDER TERMS OF COMMERCIAL AGREEMENT, BAYER WILL PURCHASE HIGH-PURITY AC-225 FROM BWXT MEDICAL AT PRE-DETERMINED PRICES Source text for Eikon: Further company coverage:

BWX Technologies, Inc. (BWXT) announced today that subsidiary BWXT Medical Ltd. has executed a commercial agreement with Bayer AG to supply high-purity Actinium-225. Today’s announcement follows the agreement reached by the two companies in September 2021. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies.

BWXT Medical, TRIUMF Agree To Manufacture High Purity Ac-225 Based Products

BWX Technologies Inc (BWXT): * BWXT MEDICAL AND TRIUMF EXECUTE AGREEMENT FOR MANUFACTURE OF HIGH PURITY AC-225 BASED PRODUCTS Source text for Eikon: Further company coverage:

BWX Technologies, Inc. (BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.

BWX Technologies Secures Contract To Build Nuclear Microreactor In US

BWX Technologies Inc (BWXT): * BWX TECHNOLOGIES (BWXT) - WILL BUILD FIRST ADVANCED NUCLEAR MICROREACTOR IN UNITED STATES UNDER A CONTRACT AWARDED BY U.S. DOD STRATEGIC CAPABILITIES OFFICE. * BWX - PROJECT PELE FULL-SCALE TRANSPORTABLE MICROREACTOR PROTOTYPE WILL BE COMPLETED, DELIVERED IN 2024 FOR TESTING AT IDAHO NATIONAL LABORATORY.

U.S. Department of Defense Strategic Capabilities Office Selects BWXT to Manufacture and Deliver Project Pele Prototype Reactor to Idaho National Laboratory in 2024 BWX Technologies, Inc. (BWXT) will build the first advanced nuclear microreactor in the United States under a contract awarded by the U.S. Department of Defense Strategic Capabilities Office. This press release features multimedia.

Pulled from Benzinga Pro data, BWX Technologies posted Q1 earnings of $59.07 million, an increase from Q4 of 49.47%. Sales dropped to $531.00 million, a 10.3% decrease between quarters. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business.